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OBJECTIVES: To characterize patient proﬁles of men asking for an erectile dysfunc-
tion (ED) treatment at the pharmacy. METHODS: Multi-center, observational, cross-
sectional study carried out in community pharmacies in Spain. Each investigator 
recruited one patient with a prescription for an ED treatment (Rx-group) and one 
patient that came into the pharmacy without prescription but asking for an ED 
 treatment (Non-Rx group). Study pharmacists completed a questionnaire asking the 
patient demographic, clinical and behavioral questions including the SHIM (Sexual 
Health Inventory for Men). RESULTS: A total of 574 pharmacists recruited 1147 
patients, whereof 1113 (97%) were included for analysis. Mean age was 58.5 (age 
range 28–91) years for the Rx-group and 54.8 (age range 21–88) years for the Non- 
Rx group (p  0.001). There was no statistical difference between the groups regarding 
weight, BMI, known hypertension, diabetes mellitus, hypercholesterolemia, dyslipid-
emia, depression and stress. Median SHIM score was 13.9 (95%CI  13.5–14.4) and 
14.0 (95%CI  13.6–14.4) for the Rx and the Non-Rx group, respectively (p  
0.7892). In the Non-Rx group, 85.1% of men asked for a PDE5 inhibitor and the 
remaining men asked for herbal remedies, food supplements or vitamins. Patients of 
both groups take about 25 months since the ﬁrst symptoms until they present with a 
health care professional. In the Non-Rx group 60,2% stated that this visit in the 
pharmacy was the ﬁrst time they had spoken with a Healthcare Professional about 
their erection problems. CONCLUSIONS: Men without a prescription for ED treat-
ment have the same degree of ED and an equal co-morbidity proﬁle as men who have 
a prescription for a PDE5 inhibitor. Therefore community pharmacists should be 
actively trained on this condition as they may play a relevant role by educating men 
about ED and encouraging them to seek further medical care, because ED might be 
a sign of underlying conditions.
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EARLY ASSESSMENT OF A NEW TREATMENT FOR ADOLESCENT 
IDIOPATHIC SCOLIOSIS
Boomkamp IS, Hummel JM, IJzerman MJ, Verkerke GB
University of Twente, Enschede, The Netherlands
OBJECTIVES: Adolescent idiopathic scoliosis (AIS) reduces the quality of life. It can 
lead to back pain, reduced back function and socio-psychological problems. Left 
untreated it may induce cardio-vascular and pulmonary problems, and even death. 
Current treatment of severe forms of idiopathic scoliosis are based on fusion of the 
vertebrae. These treatments restrict back function and growth of the adolescents. This 
study aims to conduct an early technology assessment of a new non-fusion scoliosis 
correction system. METHODS: The early assessment of this new treatment is sup-
ported by the Analytic Hierarchy Process (AHP), a technique for multi-criteria decision 
analysis. The AHP quantiﬁes the comparison between the performances of decision 
alternatives under a ﬁnite set of decision criteria. An expert panel composed of six 
technological engineers and medical specialists compared the expected performance 
of the new non-fusion treatment to the performance of posterior fusion surgery for 
patients with severe AIS. They regarded criteria related to the quality of life, complica-
tions, user friendliness and costs. RESULTS: The expert panel considered the inﬂuence 
of the treatment on the quality of life to be most important (weight 0.46) followed 
by complications (0.35), user friendliness (0.11) and costs (0.09). They expected the 
new non-fusion treatment to particularly have a more positive inﬂuence on the quality 
of life (priority 0.73) than posterior surgery has (priority 0.27). Main disadvantage 
was considered to be the relative high costs of the new treatment (priority 0.37 versus 
0.63). In overall, the new treatment is expected to slightly outperform the current 
treatment (priority 0.63 versus 0.37). CONCLUSIONS: In the absence of clinical evi-
dence, this method provides a valuable means to systematically predict a new tech-
nology’s clinical value. The outcomes provide clear directions for medical industry to 
improve the future cost-effectiveness of new treatments.
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VARIATIONS IN CHANGES OF PRESCRIBING BEHAVIORS AMONG 
PHYSICIANS AFTER THE RELEASE OF WHI REPORT
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OBJECTIVES: Findings from the Women’s Health Initiative (WHI) gave rise to the 
concerns of risk of hormone therapy (HT). This study aimed to compare physicians’ 
prescribing behavior before and after the release of WHI report in Taiwan. METHODS: 
The data source for this study comes from the outpatient claims records of the 
National Health Insurance (NHI). A cohort of 57,958 women aged 40–69 who were 
regular estrogen users for menopausal symptom were identiﬁed during January 1, 
2001 to June 30, 2001. Proportion of estrogen use, number of outpatient visits with 
estrogen prescription, and dosage of estrogen were compared on an annual basis, 
between the pre-WHI period (July 1, 2001–June 30, 2002), and the post-WHI period 
(Januray 1, 2003-December 31, 2003). Multiple logistic regressions and generalize 
estimating equation (GEE) were performed, to examine the effects of physicians’ 
characteristics on the changes in HT prescribing behavior. RESULTS: Probability of 
prescribing estrogen, number of outpatient visits with estrogen prescriptions and total 
dosage of estrogen prescription were signiﬁcantly reduced after WHI. However, the 
extents to which this consulting and prescribing behavior changes varied by physi-
cians’ characteristics: physicians of younger ages, afﬁliated with medical centers, and 
located in urban areas were less likely to prescribe estrogen, less frequently to be 
consulted at outpatient visits with estrogen prescription, and prescribed less dosages 
of estrogen, compared to their counterparts. CONCLUSIONS: The dissemination of 
information on drug safety seems to be varied by physicians’ characteristics. Strategies 
on improving the dissemination of information on drug safety,speﬁcially targeting on 
less informed physician groups, were warranted to avoid the misuse of drug with safety 
concerns.
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OBJECTIVES: This study compared efﬁcacy and safety of ﬂuticasone (FL) with 
budesonide (BUD) and beclomethasone (BDP) in 1:2 dose ratio in the treatment of 
bronchial asthma. METHODS: Comparison was based on randomized controlled 
trials (RCTs) identiﬁed by means of systematic review, carried out according to 
the Cochrane Collaboration guidelines and Agency for Technology Assessment in 
Poland. The most important medical databases (EMBASE, MEDLINE and CENTRAL) 
were searched. Two reviewers independently selected trials, assessed their quality 
and extracted data. Head-to-head comparisons were performed. RESULTS: The sys-
tematic search retrieved 15 RCTs for comparison FL vs. BUD and 18 RCTs for FL 
vs BDP, respectively. FL was signiﬁcantly more effective than BUD in respect to 
the risk of asthma exacerbations (RR  0.73 [0.59; 0.91]), change in morning Peak 
Expiratory Flow (PEF) (WMD  8.02 L/min [5.20; 10.85]) and proportion of 
symptoms-free days (MD  8.00 [2.00; 14.00]). Asthma Symptom Score (ASS) score 
didn’t differ between groups (WMD  0.24 [0.52; 0.03]). Safety analysis showed 
that FL in comparison with BUD increased the risk of hoarsness (RR  1.97 [1.07; 
3.62]) and rhinitis (RR  1.90 [1.07; 3.36]) but the incidence of other adverse 
events was comparable between those drugs. There was no statistically signiﬁcant 
difference in risk of asthma exacerbations between FL and BDP (RR  0.84 [0.61; 
1.14]). FL was associated with better improvement than BDP in respect to morning 
PEF (WMD  5.59 L/min [1.84; 9.34]), proportion of symptoms-free days (WMD  
6.43 [0.47; 12.39]) and statistically signiﬁcant reduction in ASS score (WMD  0.11 
[0.19; 0.03]). No signiﬁcant differences in safety outcomes were found between 
FL and BDP. CONCLUSIONS: Fluticasone in comparison with budesonide and 
beclomethasone in dose ratios 1:2 provides improvement in spirometric parameters 
and in comparison to budesonide descreases risk of asthma exacerbations. Safety 
proﬁles of ﬂuticasone seems to be comparable both with budesonide and 
beclomethasone.
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OBJECTIVES: The aim of this study was to compare efﬁcacy and safety of varenicline 
compared with placebo, nicotine replacement therapy or sustained-release bupropion 
for smoking cessation in adults. METHODS: Systematic review of randomized con-
trolled trials was performed to assess clinical effectiveness of varenicline according to 
guidelines of Cochrane Collaboration and HTA Agency in Poland. RESULTS: The 
clinical effectiveness analysis of varenicline compared with placebo for smoking ces-
sation in adults showed statistically signiﬁcant difference between groups in continu-
ous abstinence. Abstinence rate for weeks 9 through 12, 9 through 24 and 9 through 
52 was superior for varenicline vs placebo. The clinical effectiveness analysis of vareni-
cline in smoking adults in the context of maintaining their abstinence showed signiﬁ-
cantly greater continuous abstinence rate in weeks 13 to 24 compared with placebo. 
This advantage was maintained through the follow-up to week 52. The clinical effec-
tiveness of varenicline compared with NTZ for smoking cessation in adults showed 
that continuous abstinence rate for the last 4 weeks of 12 weeks treatment was sig-
niﬁcantly greater for varenicline (55.9%) than NRT (43.2%). In clinical effectiveness 
analysis of varenicline compared with BP, varenicline was found to be more efﬁcacious 
in continuous abstinence rates. For weeks 9 through 12, the odds ratio was 1.86(95% 
CI: 1.49; 2.33); for weeks 9–24 OR: 1.65(95% CI: 1.29; 2.11); for weeks 9–52 OR: 
1.59(95% CI: 1.21; 2.10). CONCLUSIONS: The performed analysis shows that var-
enicline is effective therapy for smoking cessation. Varenicline was more efﬁcacious 
than placebo, NTZ and bupropion SR at continuous smoking abstinence outcomes 
for the last 4 weeks of study, from weeks 9 through 24 and weeks 9 through 52. 
Varenicline more often than placebo, NTZ and bupropion SR causes nausea, insom-
nia, abnormal dreams and headache. Varenicline more effectively reduces urge to 
smoke, depressed mood, anxiety and smoking satisfaction.
